

August 8, 2025



# Poxel Announces the Opening of Reorganization Proceedings

**POXEL shares to resume trading on August 11, 2025 at market opening**

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces today the opening of reorganization proceedings.

## **Opening of judicial reorganization proceedings**

On July 29, 2025, POXEL announced in a press release that it had filed for insolvency with the Lyon Court of Economic Activities (the "**Court**") and requested the opening of reorganization proceedings.

Following a hearing held on August 5, 2025, the Court decided to initiate reorganization proceedings.

The Company will continue to operate during the six-month observation period, in accordance with legal provisions. During this period, POXEL will examine all options available to it to continue its activities, including a continuation plan.

The Company will keep all stakeholders informed as necessary of developments in its situation and the progress of the proceedings.

## **Resumption of trading in POXEL shares (Euronext: POXEL - FR0012432516)**

The Company has asked Euronext to resume trading of POXEL shares as of August 11, 2025, at market opening.

## **About Poxel**

Poxel is a **clinical stage biopharmaceutical company** developing **innovative treatments for chronic serious diseases with metabolic pathophysiology**, including **metabolic dysfunction-associated steatohepatitis (MASH)** and rare disorders. For the treatment of MASH, **PXL065** (deuterium-stabilized *R*-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney

disease (ADPKD). **TWYMEEG®** (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: [www.poxelpharma.com](http://www.poxelpharma.com)

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is otherwise not responsible for the content of external hyperlinks referred to in this press release.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250808602094/en/>

## **Contacts - Investor Relations / Media**

NewCap

Aurélie Manavarere, Théo Martin / Arthur Rouillé

[investors@poxelpharma.com](mailto:investors@poxelpharma.com)

+353 1 44 71 94 94

Source: Poxel SA